Relmada Therapeutics (RLMD) EBITDA (2012 - 2026)
Relmada Therapeutics (RLMD) EBITDA from Feb 29, 2012 to Mar 31, 2026. The TTM Relmada Therapeutics (RLMD) EBITDA is -$59M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Relmada Therapeutics (RLMD) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -22.24% |
| 3 Years TTM | -25.71% |
| 5 Years TTM | -4.28% |
| 10 Years TTM | +8.81% |
| All Time TTM | +94.17% |
Annual EBITDA change of Relmada Therapeutics (RLMD)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$19M | -66.81% |
| 2025 | -$57M | -28.24% |
| 2024 | -$80M | -19.04% |
| 2023 | -$99M | -37.09% |
| 2022 | -$157M | +24.93% |
| 2021 | -$126M | +106.64% |
| 2020 | -$61M | +302.85% |
| 2019 | -$15M | +118.52% |
| 2018 | -$6.91M | -3.09% |
| 2017 | -$7.13M | -55.88% |
| 2016 | -$16M | -5.44% |
| 2015 | -$17M | -1082.18% |
| 2014 | $1.74M | -125.70% |
| 2013 | -$6.77M | +67600.00% |
| 2012 | -$10K | N/A |
| 2011 | $0 | N/A |
Comparison Relmada Therapeutics (RLMD) five years EBITDA CAGR with competitors
Relmada Therapeutics (RLMD) five years EBITDA CAGR is -4.28%.